Biolojic Design Overview
Biolojic Design is a biopharmaceutical company dedicated to the development of human antibody-based therapeutics for cancer and other diseases. Biolojic Design has developed a new tool to re-engineer antibodies to bind new epitopes in a process known as re-epitoping. This technology has been shown to yield functional antibodies in difficult targets. Using proprietary algorithms, the company identifies an existing antibody that can be re-epitoped to bind the desired target. The antibody template is then engineered in an iterative computational and experimental approach to bind the desired epitope with high affinity. In 2014, Biolojic partnered with AstraZeneca's MedImmune LLC Biologics unit to discover antibodies for undisclosed targets selected by MedImmune, using Biolojic's computational and biochemical tools.
Cumulative Funding Raised Over Time ($)
$4.0MJan 2021
$4.0MJan 2023
$11.5MMar 2025
Latest News
growth-positive
Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros | CTech
Israeli biotech firm Biolojic Design has entered into a collaboration agreement with pharmaceutical giant Merck, potentially worth up to €346 million. The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders. In the first phase, Biolojic Design will receive slightly more than €10 million for the development of two molecules that could serve as the basis for drugs targeting cancer and several immunological disorders. The company will receive additional funding as development progresses, with the full amount contingent on the drug reaching the market and generating sales.
PartnersInvestment
growth-positive
Teva buys rights for Israeli co Biolojic's asthma treatment
Teva Pharmaceutical Industries and Biolojic Design have entered into a collaboration agreement for the development of an antibody-based therapy for asthma and atopic dermatitis. As part of the agreement, Teva will make an upfront payment and milestone payments to Biolojic. Biolojic is also eligible to receive tiered royalties in the millions of dollars on product sales if Teva successfully commercializes the therapy. The drug is currently in animal trials.
PartnersInvestment
growth-positive
Biolojic Design Appoints Ronald Herbst, Ph.D., as Chief Scientific Officer
Biolojic Design has appointed Ronald Herbst, Ph.D. as Chief Scientific Officer. Dr. Herbst brings extensive experience in the biopharmaceutical industry and will play a key role in expanding the companys U.S. operations and advancing computationally designed smart antibodies into the clinic. The appointment demonstrates the companys commitment to delivering smart therapeutics to patients. Dr. Herbsts expertise in cancer and immunology and his track record in drug development will contribute to the companys vision of revolutionizing the treatment of cancer and immunological diseases. Biolojic Design is focused on designing and developing a pipeline of revolutionary therapeutics using AI technology. The company aims to unlock the full potential of well-studied pathways in cancer and autoimmune diseases.
Management Changes
growth-positive
The Logical Song: Biolojic Design Reimagines Antibodies into "Smart" Therapeutics
Biolojic Design, a technology company based in Tel Aviv and Boston, is using computational design and AI technology to transform antibodies into intelligent medicinal solutions. The company aims to offer therapies for various diseases, with a focus on cancer and autoimmune illnesses. In April 2022, Biolojic announced that an antibody designed using its AI technology entered a clinical trial, making it the first computationally designed antibody to be tested in humans. The antibody, AU-007, is being developed by Aulos Bioscience, a Biolojic spinoff founded with $40 million in Series A funding from ATP. Biolojic Design is working on a pipeline of antibodies with novel therapeutic properties and is focused on building its own revolutionary antibodies for clinical development.
InvestmentPartners
growth-positive
Made in Israel: First AI-designed antibody could lead to eradication of tumors
Biolojic Design, an Israeli biotech company, is conducting clinical trials in Australia for its computer-designed antibody, AU-007, which is aimed at treating terminal cancer. The antibody is designed to activate a molecule known as IL-2, which can eradicate tumors. The trials have shown positive results in mice, leading to the complete elimination of tumors in over half of the subjects. The company has raised about $30 million from investors including aMoon, Keter Plastics, and Prof. Chezy Barenholz. It also co-founded a new company, Aulos Bioscience, with venture capital firm Apple Tree Partners, which invested $40 million to advance AU-007.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.95M |
| Last funding | $7.5M |
| Stage | Seed |
| Rounds | 3 |
| Investors | 4 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | biolojic.com |
| Careers | Careers page |
Locations
HaMada St 12, Rehovot, Israel
Boston, MA, USA
Photos & Videos
1 item(s)
Biolojic Design Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDigital HealthcareMedical Decision SupportTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyCore Technology
BiologicalsMoleculesArtificial IntelligenceMachine LearningTags (14)
bioconvergencetherapeuticsbioinformaticsdecision-supportnanotechnologyroboticsdigital-healthcaredrug-discoveryimmunologyhealthcarecancer-therapyantibodiesartificial-intelligencepharma-companiesGeographic Markets
GlobalBiolojic Design Financials
$3.95M
Total funding
Undisclosed
Capital raised
$7.5M
Last funding
Seed
Funding stage
3
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$4.0MJan 2021
$4.0MJan 2023
$11.5MMar 2025
Private Equity Funding
Debt Financing
Mar 2025
$7.5M
Undisclosed Round
Jan 2023
Undisclosed
Western Technology Investment
Equity crowdfunding
Jan 2021
$3.95M
OurCrowd, aMoon Fund, Winnovation
Biolojic Design Lifecycle
Cumulative Funding Raised Over Time
$4.0MJan 2021
$4.0MJan 2023
$11.5MMar 2025
All Events
Debt Financing
Mar 2025
$7.5M
Undisclosed Round
Jan 2023
Undisclosed
Western Technology Investment
Equity crowdfunding
Jan 2021
$3.95M
OurCrowd, aMoon Fund, Winnovation
Biolojic Design News
11 articles
growth-positive
Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros | CTech
Israeli biotech firm Biolojic Design has entered into a collaboration agreement with pharmaceutical giant Merck, potentially worth up to €346 million. The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders. In the first phase, Biolojic Design will receive slightly more than €10 million for the development of two molecules that could serve as the basis for drugs targeting cancer and several immunological disorders. The company will receive additional funding as development progresses, with the full amount contingent on the drug reaching the market and generating sales.
PartnersInvestment
growth-positive
Teva buys rights for Israeli co Biolojic's asthma treatment
Teva Pharmaceutical Industries and Biolojic Design have entered into a collaboration agreement for the development of an antibody-based therapy for asthma and atopic dermatitis. As part of the agreement, Teva will make an upfront payment and milestone payments to Biolojic. Biolojic is also eligible to receive tiered royalties in the millions of dollars on product sales if Teva successfully commercializes the therapy. The drug is currently in animal trials.
PartnersInvestment
growth-positive
Biolojic Design Appoints Ronald Herbst, Ph.D., as Chief Scientific Officer
Biolojic Design has appointed Ronald Herbst, Ph.D. as Chief Scientific Officer. Dr. Herbst brings extensive experience in the biopharmaceutical industry and will play a key role in expanding the companys U.S. operations and advancing computationally designed smart antibodies into the clinic. The appointment demonstrates the companys commitment to delivering smart therapeutics to patients. Dr. Herbsts expertise in cancer and immunology and his track record in drug development will contribute to the companys vision of revolutionizing the treatment of cancer and immunological diseases. Biolojic Design is focused on designing and developing a pipeline of revolutionary therapeutics using AI technology. The company aims to unlock the full potential of well-studied pathways in cancer and autoimmune diseases.
Management Changes
growth-positive
The Logical Song: Biolojic Design Reimagines Antibodies into "Smart" Therapeutics
Biolojic Design, a technology company based in Tel Aviv and Boston, is using computational design and AI technology to transform antibodies into intelligent medicinal solutions. The company aims to offer therapies for various diseases, with a focus on cancer and autoimmune illnesses. In April 2022, Biolojic announced that an antibody designed using its AI technology entered a clinical trial, making it the first computationally designed antibody to be tested in humans. The antibody, AU-007, is being developed by Aulos Bioscience, a Biolojic spinoff founded with $40 million in Series A funding from ATP. Biolojic Design is working on a pipeline of antibodies with novel therapeutic properties and is focused on building its own revolutionary antibodies for clinical development.
InvestmentPartners
growth-positive
Made in Israel: First AI-designed antibody could lead to eradication of tumors
Biolojic Design, an Israeli biotech company, is conducting clinical trials in Australia for its computer-designed antibody, AU-007, which is aimed at treating terminal cancer. The antibody is designed to activate a molecule known as IL-2, which can eradicate tumors. The trials have shown positive results in mice, leading to the complete elimination of tumors in over half of the subjects. The company has raised about $30 million from investors including aMoon, Keter Plastics, and Prof. Chezy Barenholz. It also co-founded a new company, Aulos Bioscience, with venture capital firm Apple Tree Partners, which invested $40 million to advance AU-007.
InvestmentPartners
growth-positive
First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients
Biolojic Design, a technology company, announced that a computationally designed antibody will enter a clinical trial. The antibody, AU-007, was designed to eradicate solid cancer tumors by harnessing the bodys own interleukin-2 (IL-2). The antibody was transferred to Aulos Bioscience, a Biolojic spinoff, for clinical trials. Biolojic Design has partnerships with Nektar Therapeutics and Eli Lilly for the development of antibodies against autoimmune diseases and diabetes, respectively. Aulos Bioscience received $40 million in Series A funding from ATP to advance AU-007. Biolojic Design is also planning to start clinical trials with the first ever multi-specific antibody in 2023. The company aims to expand its presence and leadership in the U.S. with Boston as its base of operations.
PartnersInvestment
growth-positive
The man making antibodies smarter
Biolojic Design, a company that develops smart antibodies to treat a variety of diseases, is working to revolutionize the pharmaceutical industry. The company uses computational mathematics, big data, and artificial intelligence to develop and program antibodies. Unlike traditional antibodies, these smart antibodies can adapt to changing situations. Biolojic Design has already signed collaboration agreements with pharmaceutical giants like Eli Lilly and Nektar Therapeutics. The company has also raised over $120 million in funding.
PartnersInvestment
הסיפור המדהים על המרדף אחר נוגדן שיציל את העולם ממחלות
growth-positive
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes
Eli Lilly and Biolojic Design have announced a research collaboration and license agreement to develop a potential antibody-based therapy for diabetes. Biolojics AI-based multibody platform will be used in the discovery and development process. Under the agreement, Lilly will pay research fees and Biolojic is eligible to receive up to $121 million in potential development and commercialization milestones. Biolojic may also receive royalties on product sales. The specific targets for the therapy were not disclosed. The collaboration allows Lilly to explore novel methods for developing new medicines, while Biolojic can apply its platform to design potential therapies for diabetes.
Partners
growth-positive
Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease
Biolojic Design has entered into a research collaboration and license option agreement with Nektar Therapeutics to discover and develop agonistic antibodies for the treatment of autoimmune disease. The financial terms of the transaction were not disclosed. Biolojic Designs AI-based platform designs antibodies that target specific epitopes with precision and carry out functions previously not possible. The collaboration with Nektar allows Biolojic to leverage their computational capabilities and assets to investigate a new target for the potential treatment of autoimmune disease.
Partners
growth-positive
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
Aulos Bioscience, a new company created with $40 million in Series A funding from ATP and Biolojic Design, is developing IL-2-binding monoclonal antibodies as therapeutics against solid tumors. The antibodies are computationally designed to redirect IL-2 to effector T-cells and away from regulatory T-cells, potentially enhancing immune activation. Aulos Bioscience aims to revolutionize cancer treatment and plans to start human trials later this year. The company will be based in Cambridge, MA, and will be presented at the J.P. Morgan Healthcare Conference on January 14, 2021.
Investment
Biolojic Design Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 94 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
Biolojic Design Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 514201391 |
| Crunchbase | biolojic-design |
| Phone | +97235270600 |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-02-29T00:00:00.000Z |
| Created | 2015-01-08T00:00:00.000Z |
| Claimed | Yes |